Lipotropin HCL AOD-9604: Benefits, Dosing, and Safety Explained

Lipotropin HCL AOD-9604 is a synthetic fragment of human growth hormone that was developed as an anti-obesity drug and is now sold online as a research chemical. It is designed to copy the fat-metabolizing portion of hGH without the hormone's effects on blood sugar or IGF-1. Human trials produced mixed results, it has never been approved by the FDA for any use, and it is banned in competitive sport.

What Lipotropin HCL AOD-9604 Actually Is

Lipotropin HCL is a product name rather than a distinct drug. The compound inside the vial is AOD-9604, a short synthetic peptide modeled on the tail end of human growth hormone, the region spanning amino acids 176 through 191. Researchers modified that fragment so it would survive longer in the body than the raw hGH tail.

The word lipotropin is marketing shorthand for fat-affecting. It should not be confused with beta-lipotropin, a naturally occurring pituitary hormone involved in stress and appetite signaling, which is a completely different molecule.

The peptide was developed in the 1990s at Monash University in Australia and later licensed to Metabolic Pharmaceuticals. Vendors often list it as lipotropin hcl-aod 9604, but both names point to the same 16-amino-acid research peptide.

How AOD-9604 Is Supposed to Work

Growth hormone influences fat tissue through a small region near its tail end. AOD-9604 keeps that region but is too short to activate the full growth hormone receptor, so the theory is that it delivers the fat-burning signal without raising IGF-1 or disturbing glucose metabolism.

• In isolated fat cells, AOD-9604 has been shown to stimulate lipolysis, the breakdown of stored fat, and to inhibit lipogenesis, the creation of new fat.
• In animal models, treated animals lost body fat without measurable changes in blood glucose or IGF-1.
• The peptide does not appear to suppress appetite, which separates it mechanistically from GLP-1 medications.

Those findings come from laboratory and animal work. Whether the same effects occur in people is the part that remains unresolved.

What Human Research Has Shown

Small human studies in the early 2000s tested roughly 1 mg per day by subcutaneous injection in obese adults. Some participants lost body fat, but the trials were small and the changes were modest rather than dramatic.

A larger Phase IIb obesity trial did not meet its weight-loss endpoint, and the sponsor discontinued development for that indication. Later work explored oral and transdermal delivery and other uses such as cartilage repair, also without producing an approved product.

Most reviews of the peptide circulating online are personal anecdotes posted in forums or on vendor pages. They are not controlled studies, and they frequently contradict one another about how much fat users actually lost.

AOD 9604 Dosage Used in Research

There is no established aod 9604 dosage for humans, because the compound has never been approved and no formal dose-finding program was completed. The figures below come from published trials and from protocols users discuss online. They are not medical recommendations.

Setting	Reported amount	Frequency and route
Early human trial in obesity	About 1 mg per day	Once daily, subcutaneous
Phase IIb obesity program	Doses reported in the 1 mg range	Once daily, subcutaneous
Community protocols	250 to 500 mcg per day	Once or twice daily, subcutaneous
Laboratory research	Micromolar concentrations	Cell culture only

Community guidance usually recommends injecting on an empty stomach, often in the morning, because insulin spikes after eating are thought to blunt the peptide's effect. That reasoning is theoretical, and no clinical trial has tested timing.

Users also debate cycle length, typically four to twelve weeks with a break in between. None of those schedules has been validated in controlled human research.

AOD 9604 Reconstitution Basics

Correct aod 9604 reconstitution matters more than most users expect, because an error in the math can throw a dose off by a factor of ten. The peptide ships as a lyophilized powder and has to be dissolved in bacteriostatic water before use.

1. Draw the chosen volume of bacteriostatic water with a sterile syringe.
2. Inject the water slowly down the inside wall of the vial instead of directly onto the powder.
3. Swirl gently until the powder dissolves. Do not shake, because agitation can damage the peptide.
4. Refrigerate the reconstituted vial at 2 to 8 degrees Celsius and keep it out of direct light.

A 2 mg vial mixed with 2 mL of water yields 1,000 mcg per mL, so a 300 mcg dose would measure 0.3 mL on an insulin syringe. A 5 mg vial mixed with 2 mL of water yields 2,500 mcg per mL, so the same 300 mcg dose would measure 0.12 mL.

These are laboratory handling steps, not instructions for human use. AOD-9604 is not manufactured to the sterility standards required of an approved injectable drug, and contamination is one of the main practical risks with any gray-market peptide.

AOD 9604 Benefits and Side Effects: What Is Documented

Any honest discussion of aod 9604 benefits and side effects has to separate published findings from internet anecdotes.

• Documented: AOD-9604 does not appear to raise IGF-1 or blood glucose in the studies published so far, which is the main theoretical advantage over growth hormone itself.
• Reported: Users describe gradual fat loss over several weeks, especially around the midsection, along with injection-site irritation, headaches, and occasional fatigue.
• Unknown: Long-term effects, use during pregnancy, and interactions with prescription medications have not been studied.

AOD-9604 is not approved by the FDA for human use in the United States. The World Anti-Doping Agency lists AOD-9604 as a prohibited substance, and the peptide was at the center of a high-profile Australian sports doping investigation in 2013.

Anyone considering a research peptide should speak with a licensed healthcare professional first, especially if they take medication for diabetes, thyroid disease, or a bleeding disorder.

How AOD-9604 Compares to Other Peptides

People often encounter AOD-9604 while comparing it with prescription and experimental alternatives. The three compounds below are frequently mentioned together, but they work through different mechanisms.

Feature	AOD-9604	Tesamorelin	MOTS-c
Class	Growth hormone fragment peptide	GHRH analog	Mitochondrial-derived peptide
FDA status	Not approved for any use	Approved for HIV-associated lipodystrophy	Not approved for any use
Effect on IGF-1	Little to none reported	Raises IGF-1	Not established
Main research focus	Fat metabolism	Visceral fat reduction	Insulin sensitivity and metabolic regulation
Typical route studied	Subcutaneous injection	Subcutaneous injection	Subcutaneous injection

The aod 9604 vs tesamorelin comparison usually comes down to approval status and IGF-1. Tesamorelin is a legitimate prescription drug with a defined indication, while AOD-9604 is not approved in any country and cannot be compared on clinical footing.

The aod 9604 vs mots-c comparison is even less settled. MOTS-c acts on cellular energy metabolism rather than directly on fat-cell signaling, and it has no completed human trials.

Stacking AOD-9604 with a GLP-1 and GIP medication such as tirzepatide is a popular topic in forums. Tirzepatide is FDA-approved for weight management and has strong clinical data, while AOD-9604 has none and no published study has examined the combination.

The Bottom Line

AOD-9604 is an interesting laboratory molecule that never became a medicine. It is not approved by the FDA, it is banned in sport, and the human evidence for meaningful fat loss is weak. Anyone selling it is selling a research chemical, and anyone using it is running an unmonitored personal experiment.

COMMON QUESTIONS

Frequently Asked Questions

Is AOD-9604 FDA approved?

No. AOD-9604 is not approved by the FDA for weight loss or any other human use in the United States, and it is sold online only as a research chemical. A Phase IIb obesity trial failed to meet its weight-loss endpoint, and the sponsor discontinued development for that indication.

What AOD 9604 dosage is used in research?

Early human studies used about 1 mg per day injected under the skin, while community protocols commonly cite 250 to 500 mcg per day. No dose-finding studies were ever completed, so there is no FDA-approved dose. Anyone considering it should discuss the risks with a healthcare professional first.

Does AOD-9604 have side effects?

Reported side effects include injection-site irritation, headache, and fatigue, though these come from user anecdotes rather than controlled trials. Because the peptide is not FDA-approved and is sold without pharmaceutical quality control, contamination and dosing errors are real risks. Long-term safety data do not exist.